After learning about the Valsartan recall due to contamination, many patients were switched from Valsartan to other sartan drugs. But now many are questioning the safety of these sartan drugs after learning that the European Medicines Agency (EMA) is investigating candesartan, irbesartan, losartan, and olmesartan for the same reason. It’s only a matter of time before the EMA and FDA determine if there should be a sartan drug recall.
The EMA announced that low levels of N-nitrosodiethylamine (NDEA) were detected in losartan, prompting the precautionary investigation into other sartan drugs because of the similar chemical structure. “National authorities in the EU are currently considering whether to recall medicines containing Aurobindo Pharma’s irbesartan from pharmacies as a precaution,” the EMA said.
The EMA will be increasing supervision on Chinese company Zheijiang Huahai to review the manufacturing process of other active substances. The investigation will help the European Commission to determine if there should be a sartan drug recall.
If the European Union decides to issue a sartan drug recall, the FDA may follow suit. GoldenbergLaw will continue to update on the Valsartan and sartan investigation.
If you or a loved one took Valsartan and was diagnosed with liver cancer, stomach cancer, colorectal cancer, intestinal cancer, esophageal cancer, prostate cancer, pancreatic cancer, non-hodgkin’s lymphoma, leukemia, or multiple myeloma, please contact us. We have successfully resolved similar cases, including many involving the high blood pressure medication Benicar. Call GoldenbergLaw, and leave the sleepless nights to us.